Our values

Our values – developed together as an organisation – make it clear how each and every one of us work to meet our mission – to make the discoveries that defeat cancer.

Our six values are:

ICR-values-icons-pursuing-excellence-SQUARE

Pursuing excellence: We aspire to excellence in everything we do, and aim to be leaders in our fields.

ICR-values-icons-acting-with-integrity-SQUARE

Acting with integrity: We promote an open and honest environment that gives credit and acknowledges mistakes, so that our actions stand up to scrutiny.

ICR-values-icons-valuing-all-our-people-SQUARE

Valuing all our people: We value the contribution of all our people, help them reach their full potential, and treat everyone with kindness and respect.

ICR-values-icons-working-together-SQUARE

Working together: We collaborate with colleagues and partners to bring together different skills, resources and perspectives.

ICR-values-icons-leading-innovation-SQUARE
Leading innovation: We do things differently in ways that no one else has done before, and share the expertise and learning we gain. 

Making a difference: We all play our part, doing a little bit more, a little bit better, to help improve the lives of people with cancer. 

Related news

Image: Blood samples. Credit: Ahmad Ardity via Pixabay
Genetic testing for Lynch Syndrome prevents cancers being missed

17/01/25

Genetic testing to identify women with Lynch Syndrome is likely to need to increase dramatically to ensure that carriers are not missed, a new analysis by ICR researchers has found.
See full story

Related blogs

ICR Logo
“Becoming a cancer patient has given me extra perspective” – Paul’s story

02/10/24 - Andrea Kohn

Professor Paul Workman is Harrap Professor of Pharmacology and Therapeutics at The Institute of Cancer Research. He has worked in the field of cancer research for more than 50 years and was the ICR’s Chief Executive and President from 2014 to 2021. During his leadership, he oversaw many of our scientific successes – including the development of smarter and kinder forms of radiotherapy. Now, after being diagnosed with prostate cancer himself in 2022, he reflects on his experience as both a leading cancer scientist and now a cancer patient.
See full story